natalizumab elan pharma
elan pharma international ltd. - natalizumabot - crohn-betegség - immunostimulants, - kezelés a közepesen súlyos, aktív crohn-betegség csökkentésére tünetek, valamint az indukciós, karbantartás tartós válasz, illetve elengedése, azoknál a betegeknél, akik nem reagáltak annak ellenére, hogy teljes körű, megfelelő terápia egy kortikoszteroid egy immunszuppresszív; vagy intoleráns vagy orvosi ellenjavallat, hogy az ilyen terápiák.
tysabri
biogen netherlands b.v. - natalizumabot - szklerózis multiplex - szelektív immunszuppresszánsok - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tyruko
sandoz gmbh - natalizumabot - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
bonaxon 0,5 mg kemény kapszula
egis gyógyszergyár zrt. - fingolimod -
chantico 0,5 mg kemény kapszula
g.l. pharma gmbh - fingolimod -
efigalo 0,5 mg kemény kapszula
krka d.d., - fingolimod -
fimodigo 0,5 mg kemény kapszula
vipharm s.a. - fingolimod -
fingolimod alvogen 0,5 mg kemény kapszula
zentiva, k.s. (csehország) - fingolimod -
fingolimod stada 0,5 mg kemény kapszula
stada arzneimittel ag - fingolimod -